OPEN END-TURBO-OPTIONSSCHEIN - VIATRIS Stock

Certificat

DE000HG1G8J3

Market Closed - BOERSE MUENCHEN 15:35:45 2024-06-28 EDT
2.25 EUR +5.63% Intraday chart for OPEN END-TURBO-OPTIONSSCHEIN - VIATRIS
Current month+4.65%
1 month+7.14%
Date Price Change
24-06-28 2.25 +5.63%
24-06-27 2.13 +4.41%
24-06-26 2.04 +6.81%
24-06-25 1.91 -13.57%
24-06-24 2.21 +10.50%

Real-time BOERSE MUENCHEN

Last update June 28, 2024 at 03:35 pm

More quotes

Static data

Product typeCertificat Turbo
Buy / SellCALL
Underlying VIATRIS INC.
Issuer HSBC
WKN HG1G8J
ISINDE000HG1G8J3
Date issued 2022-03-02
Strike 8.338 $
Maturity Unlimited
Parity 1 : 1
Emission price 3.57
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 5.03
Lowest since issue 0.78

Company Profile

Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Company’s ARV franchise. The Company’s portfolio comprises approved molecules across a range of key therapeutic areas, including globally recognized iconic and key brands and generics, including complex products. The Company operates approximately 30 manufacturing sites worldwide that produce oral solid doses, injectables and complex dosage forms.
Sector
-
More about the company

Ratings for Viatris Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Consensus: Viatris Inc.

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
10
Last Close Price
10.63 USD
Average target price
12.4 USD
Spread / Average Target
+16.62%
Consensus